Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study.
نویسندگان
چکیده
OBJECTIVE To evaluate the efficacy and safety of 3 months of vaginal mifepristone treatment on leiomyoma volume and related symptoms. DESIGN Prospective, open-label, two tertiary centers, phase II clinical trial. SETTING Two tertiary medical centers in Israel. PATIENT(S) Thirty-three enrolled women, ages 30-53 years, diagnosed with symptomatic uterine fibroids. INTERVENTION(S) Patients received 10 mg mifepristone vaginally daily for 3 months. MAIN OUTCOME MEASURE(S) Reduction in uterine leiomyoma volume. Improvement in symptoms related to uterine fibroids was assessed with the use of the "Uterine Fibroid Symptoms Quality of Life Questionnaire" (UFS-QoL). The number of bleeding days, safety, and tolerability were secondary measures. RESULT(S) Mifepristone treatment significantly reduced leiomyoma volume from 135.3 ± 22.9 cc at enrollment to 101.2 ± 22.4 cc after 3 months of treatment. The UFS-QoL Score significantly decreased from 20.7 ± 0.7 at enrollment to 14.0 ± 0.8 after 3 months of treatment. The number of bleeding days significantly decreased by 3.5 days. Endometrial biopsies showed no evidence of endometrial hyperplasia or cellular atypia. There were no major side effects during the course of the study, and treatment was well tolerated. CONCLUSION(S) Vaginal mifepristone may offer an effective treatment option for women with symptomatic uterine leiomyoma and can improve the patients' quality of life. CLINICAL TRIAL REGISTRATION NUMBER NCT00881140.
منابع مشابه
Sustained relief of leiomyoma symptoms by using focused ultrasound surgery.
OBJECTIVE To assess several measures of the long-term outcome of magnetic resonance-guided focused ultrasound surgery for symptomatic uterine leiomyomata. METHODS Data on 359 women completing 24-month follow-up in all clinical trials of magnetic resonance-guided focused ultrasound surgery for uterine leiomyomata were analyzed. Quality of life outcomes, measured by the symptom severity score o...
متن کاملMifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery
OBJECTIVES To evaluate the efficacy and safety of 2.5 mg and 5 mg mifepristone during 3 months for the treatment of uterine fibroids before surgery. DESIGN Multicenter randomized clinical trial. LOCATIONS Eusebio Hernández Hospital, Havana, Cuba and the Alemán Hospital, Managua, Nicaragua. SUBJECTS Included in the study were 146 women with symptomatic uterine fibroids. TREATMENT GROUP I...
متن کاملEfficacy and Safety of Aripiprazole for Treatment of Irritability in Children with Autistic Disorder: An Open-Label Study
متن کامل
Predictors of uterine evacuation following early medical abortion with mifepristone and misoprostol.
OBJECTIVES We sought to determine predictors of uterine evacuation for women undergoing medical abortion using mifepristone and vaginal misoprostol through 63 days' gestation. STUDY DESIGN We pooled data from two prospective multicenter medical abortion trials. In one study, women received mifepristone 200 mg followed either 6-8 or 23-25 h later by misoprostol 800 mcg vaginally. In the second...
متن کاملEffects of mifepristone on uterine leiomyoma in premenopausal women: a meta-analysis.
OBJECTIVE To conduct a meta-analysis of the studies assessing the effects of mifepristone on the uterus, uterine leiomyoma, and leiomyoma-related symptoms in premenopausal women. DESIGN Meta-analysis. SETTING Centers for reproductive care. PATIENT(S) Premenopausal women who suffered from leiomyoma. INTERVENTION(S) We identified all of the studies published before December 2012 that comp...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Fertility and sterility
دوره 101 2 شماره
صفحات -
تاریخ انتشار 2014